Severe Dermatologic Toxicity During Amivantamab-Lazertinib Treatment in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Chloe M Jones, Matthew M Delancy, Steven Bonawitz · 2026
Read Severe Dermatologic Toxicity During Amivantamab-Lazertinib Treatment in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer by Chloe M Jones, Matthew M Delancy, Steven Bonawitz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13629737.txt.
Description
Chloe Jones, Matthew Delancy, and Steven Bonawitz reported in 2026 a severe skin reaction in a woman treated with two targeted drugs for lung cancer that had spread to the brain. The drug pair works well but is known for skin harm. She came in with drainage from a scalp cut made five months earlier for tumor surgery.
Surgery to check the wound found no infection or open wound, but a patch of raw, ulcerated tissue along the cut. Drug care was paused, then one drug was restarted, and later standard drugs were used as cancer grew. The report reviews skin care steps that can cut severe scalp reactions a great deal.
Catalog record
| CREATOR | Chloe M Jones, Matthew M Delancy, Steven Bonawitz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |